Investigating Collamer's accommodation

Article

STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL).

STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL).

The Collamer material, a proprietary pure collagen copolymer that STAAR claims is similar to the crystalline lens, is also used in the company's Visian ICL. Lenses made using Collamer have had FDA approval since 2000; the distribution of the high water content of the Collamer lens, its biocompatibility and bio-adhesive properties have raised hopes that Collamer will prove a suitable material for accommodative lenses.

Phase I of the CAST study will assess the Collamer Aspheric Single Piece Lens by gathering near and distance visual acuity data; Phase II will evaluate the accommodative properties of the lens after the implementation of changes made to maximize accommodation and compare these with the accommodation data gathered in Phase I. If Phase II shows superior accommodation properties, STAAR plans to make the adjusted lens available next year, and may seek a new labelling claim from the FDA. Phase III will assess a new design of Collamer lens.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.